questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the withdrawal of Bluebird Bio from the (a) UK and (b) European market on access to gene therapy treatment for people with (i) beta thalassemi
answerText: No assessment has been made of the potential impact of the withdrawal of Bluebird Bio from the United Kingdom and European markets on access to gene therapy treatment for people with beta thalassemia and cerebral adrenoleukodystrophy. NHS England continue...
heading: Adrenoleukodystrophy and Thalassaemia: Gene Therapies